17 December 2019 (Tuesday) - Haemostasis

The A.S.H. sent an update on haemostasis today:

Romiplostim Improves Platelet Counts, Chemotherapy Adherence in Patients With Chemotherapy-Induced Thrombocytopenia
Patients with solid tumor cancers were able to continue treatment with chemotherapy with fewer delays and dose reductions, though efficacy was less robust in patients with lymphoid malignancies.

Registry Analysis Finds Off-Label Rituximab Improves Outcomes in Patients With iTTP
In subgroup analyses, the authors also noted that Caucasian patients with relapsed iTTP had significantly longer relapse-free survival, compared with African American patients.

Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment
The two FDA-approved thrombopoietin receptor agonists were associated with lower risks of complications for patients whose disease failed to respond to corticosteroids.

No comments:

Post a comment